Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer

Theranostics – i.e., the combination of molecular imaging and radiopharmaceutical therapy of cancer targeting a common biological feature – is a rapidly expanding field owing the recent successes of novel radiopharmaceutical therapies, such as (177)Lu-based prostate-specific membrane antigen radioli...

Descripción completa

Detalles Bibliográficos
Autor principal: Beauregard, Jean-Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733022/
https://www.ncbi.nlm.nih.gov/pubmed/36494731
http://dx.doi.org/10.1186/s40644-022-00505-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733022/
https://www.ncbi.nlm.nih.gov/pubmed/36494731
http://dx.doi.org/10.1186/s40644-022-00505-y

Ejemplares similares